Catalent, Inc. has completed the previously announced offer by Catalent Boston, Inc., a subsidiary of Catalent Pharma Solutions, Inc., to acquire all outstanding shares of Juniper Pharmaceuticals, Inc. for $11.50 per share. The acquisition expands Catalent’s offerings in formulation development, bioavailability solutions and clinical-scale oral dose manufacturing, and complements its integrated global clinical and commercial supply network. As a result of the merger, Juniper will become a wholly...